碧迪医疗 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedDecember 31, 2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission file number 001-4802 Becton, Dickinson and Company (Exact name of registrant as specified in its charter) New Jersey(State or other jurisdiction ofincorporation or organization) 22-0760120 (I.R.S. EmployerIdentification No.) 1 Becton Drive,Franklin Lakes,New Jersey07417-1880(Address of principal executive offices) (Zip Code) (201) 847-6800 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common stock, par value $1.001.900% Notes due December 15, 20261.208% Notes due June 4, 20261.213% Notes due February 12, 20363.519% Notes due February 8, 20313.828% Notes due June 7, 2032 New York Stock ExchangeNew York Stock ExchangeNew York Stock ExchangeNew York Stock ExchangeNew York Stock ExchangeNew York Stock Exchange Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, andemerging growth company in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒There were 284,741,809 shares of Common Stock, $1.00 par value, outstanding at December31, 2025. BECTON, DICKINSON AND COMPANYFORM 10-QFor the quarterly period ended December31, 2025 TABLE OF CONTENTS Part I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Condensed Consolidated Statements of Income3Condensed Consolidated Statements of Comprehensive Income4Condensed Consolidated Balance Sheets5Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures About Market Risk41Item 4.Controls and Procedures41Part II.OTHER INFORMATIONItem 1.Legal Proceedings42Item 1A.Risk Factors43Item 2.Unregistered Sales of Equity Securities and Use of Proceeds43Item 3.Defaults Upon Senior Securities44Item 4.Mine Safety Disclosures44Item 5.Other Information44Item 6.Exhibits44Signatures45 BECTON, DICKINSON AND COMPANYCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEMillions of dollars(Unaudited) BECTON, DICKINSON AND COMPANYNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSDecember31, 2025 Note 1 – Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments whichare of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for theperiods presented. However, the financial statements do not include all information and accompanying notes required for a presentation inaccordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements shouldbe read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2025 Annual Report onForm 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers fordisclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results ofoperations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. Combination of Biosciences and Diagnosti